Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE8A | O60658 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19628755 | 0.81 | KDM4C (0.61) | KDM4CKDM2BPHF8KDM5BKDM5A | |
| SCHEMBL16033927 | 0.80 | KDM4C (0.41) | KDM4CKDM2BPHF8KDM5BKDM5A | |
| SCHEMBL19628765 | 0.74 | KDM4C (0.74) | KDM4CKDM2BPHF8KDM5BKDM5A | |
| SCHEMBL19628763 | 0.71 | KDM5B (0.62) | KDM4CKDM2BKDM5BKDM5A | |
| SCHEMBL16033852 | 0.66 | PHF8 (0.51) | KDM4CKDM2BPHF8KDM5BKDM5A | |
| SCHEMBL16034004 | 0.65 | KDM4C (0.41) | KDM4CKDM2BPHF8ALDH1A1 | |
| SCHEMBL16126232 | 0.65 | KDM4C (0.38) | KDM4CKDM2BPHF8 | |
| SCHEMBL827247 | 0.65 | CCR1 (0.48) | ALDH1A1MAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL19628756 | 0.64 | KDM2B (0.51) | KDM4CKDM2BPHF8KDM5BKDM5A | |
| SCHEMBL3303214 | 0.64 | NPC1 (0.51) | ALDH1A1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM2B 19/4885PHF8 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.